New research from the Paris Brain Institute shows how a simple blood test can now diagnose De Vivo disease
Glut1 deficiency syndrome is a rare and disabling neurological disease still relatively unknown to the medical community.
A mutation in the SLC2A1 gene in affected patients causes the glucose transporter GLUT1 to malfunction.
Since this transporter is responsible for the glucose entering glial cells, the brain is deprived of some of the sugar it needs to function correctly, leading to seizures, bouts of abnormal movement, and developmental delays.
These symptoms can be improved by managing the metabolic disorder that causes the disease via a high-fat diet, known as the ketogenic diet.
In addition, promising new therapeutic molecules designed to compensate for the poor supply of glucose to brain cells are currently being evaluated.
“There is an urgent need to identify them better since many are missing or diagnosed too late.”
- Innovative treatment targets blood clots without increased bleeding risk
- Chronic blood cancer transition to aggressive disease revealed
- Genetic therapy could be a turning point for MND
The incidence of Glut1 deficiency syndrome is estimated to be 1 in 24,000 in the general population.
This figure is probably underestimated, as it only considers epileptic patients and not those with isolated, non-specific symptoms such as learning disabilities or abnormal movements.
The diagnosis is even more challenging to make because it was previously based on a lumbar puncture supplemented by genetic tests.
Mochel added: “This invasive, often lengthy, and expensive procedure significantly limits access to care. Hence the interest in looking for a blood biomarker to enable a rapid diagnosis of Glut1 deficiency syndrome.”
Indeed, the GLUT1 transporter is not only abundant in endothelial and glial cells of the brain; it also binds to the surface of erythrocytes, the red blood cells.
The diagnostic test designed by the Paris-based medtech METAFORA biosystems makes it possible to quantify GLUT1 on their surface by flow cytometry, a technique routinely used in analysis laboratories.
A simple blood sample is required to perform the test without the need to take a fasting patient. The result is available in 48 to 72 hours.
To validate the new test – METAglut1 – teams from AP-HP and 33 French clinical investigation centres, under the direction of Mochel, the study’s principal investigator, recruited 549 patients in a prospective cohort – that is to say, people in whom the disease was suspected – and 87 patients from a retrospective cohort, already diagnosed.
The goal was To compare the efficacy and accuracy of METAglut1 with the reference diagnostic test requiring cerebrospinal fluid sampling and genetic analysis.
The researchers’ results indicate that METAglut1 has a sensitivity of about 80%, a specificity of more than 99%, and a high predictive value, a performance comparable to the reference test.
Mochel said: “These data allow us to validate the benefit of the test formally.
“It will make it possible to look for Glut1 deficiency syndrome in many patients simply and quickly.
“In the event of a positive result, treatment can be started immediately, significantly improving the prognosis, especially for children in the midst of brain development.”
Therefore, the study’s authors recommend that the test be performed in all children from three months of age and adults with intellectual disability, neurodevelopmental disorders, abnormal movements, or epilepsy – especially if it is drug-resistant and if a ketogenic diet alleviates the seizures.
Indeed, if used at an early symptomatic stage, METAglut1 can immediately identify 80% of patients with Glut1 deficiency syndrome.
For this reason, French National Authority for Health recommends its reimbursement, which paves the way for its adoption in Europe and the US.
Image: Blood cells. Credit: Wellcome collection. Public Domain.